Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neuroblastoma 11Triple Negative Breast Neoplasms 1Osteosarcoma 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Cyclophosphamide 12Specimen Handling 9cabozantinib 8X-Rays 8Magnetic Resonance Spectroscopy 8fludarabine 7Phantoms, Imaging 7Biopsy 7Temozolomide 6Gemcitabine 5regorafenib 4pembrolizumab 4Vincristine 4Nuclear Medicine Department, Hospital 4Nivolumab 4Methotrexate 4Doxorubicin 4olaparib 3irinotecan sucrosofate 3fludarabine phosphate 3dinutuximab 3Zoledronic Acid 3Surveys and Questionnaires 3Irinotecan 3Ifosfamide 3Cisplatin 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Osteosarcoma × naxitamab × 1 year × Clear all
NCT02502786 2025-10-07

Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
46 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡